Johnson & Johnson’s prostate cancer drug shrinks tumours in early-stage trial
TimesLive | 24.10.2026 16:30
Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumours to disappear or shrink in an early-stage trial.
